ARNA - Arena Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
814,300
17,970
21,337
123,975
38,326
Cost of Revenue
-
-
-
15,341
13,175
Gross Profit
-
-
-
108,634
25,151
Operating Expenses
Research Development
163,308
115,029
70,988
66,425
88,411
Selling General and Administrative
61,000
47,724
30,341
31,243
35,966
Total Operating Expenses
238,881
162,753
101,329
97,668
124,377
Operating Income or Loss
575,419
-144,783
-79,992
10,966
-99,226
Interest Expense
5,238
5,695
6,119
6,512
6,828
Total Other Income/Expenses Net
3,550
2,872
-11,975
-27,640
-2,083
Income Before Tax
593,196
-138,834
-95,854
-22,896
-107,979
Income Tax Expense
68
-110,265
-
-
-
Income from Continuing Operations
593,128
-28,569
-95,854
-22,896
-107,979
Net Income
593,128
-29,399
-91,407
-22,516
-107,979
Net Income available to common shareholders
593,128
-29,399
-91,407
-22,516
-107,979
Reported EPS
Basic
-
-0.63
-2.77
-0.90
-4.50
Diluted
-
-0.63
-2.77
-0.90
-4.50
Weighted average shares outstanding
Basic
-
47,041
32,990
24,313
24,067
Diluted
-
47,041
32,990
24,313
24,067
EBITDA
-
-144,783
-79,992
-16,384
-101,151